Claims
- 1) A compound of the formula (I),
- 2) The compound according to claim 1, wherein
R1 denotes hydrogen, R2 denotes a group selected from among a CHO, OH, and CH3 group, R3, R4 are identical or different and denote a group selected from among hydrogen, optionally substituted C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C3-C7-cycloalkyl, or R3 and R4 together denote a C2-C5-alkyl bridge, R5 denotes a group selected from among optionally substituted C1-C10-alkyl, C2-C10-alkenyl, C2-C10-alkynyl, C3-C6-cycloalkyl and C3-C6-cycloalkenyl, or R3 and R5 or R4 and R5 together denote a saturated or unsaturated C3-C4-alkyl bridge which may contain 1 to 2 heteroatoms, and R7 denotes hydrogen.
- 3) The compound according to claim 2, wherein
R1-R5, R7, R8 and X have the meaning indicated, and R6 denotes a group of general formula 1369wherein n denotes 1, 2, 3 or 4, R9 denotes a group selected from among optionally substituted C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, —CONH—C1-C10-alkylene, —O-aryl, —O-heteroaryl, —O-cycloalkyl, —O-heterocycloalkyl, aryl, heteroaryl, cycloalkyl and heterocycloalkyl or a group selected from among —O—C1-C6-alkyl-Q1, —CONR8—C1-C10-alkyl-Q1, —CONR8—C2-C10-alkenyl-Q1, —CONR8—Q2, halogen, OH, —SO2R8, —SO2N(R8)2, —COR8, —COOR8, —N(R8)2, —NHCOR8, CONR8OC1-C10 alkylQ1 and CONR8OQ2, Q1 denotes hydrogen, —NHCOR8, or a group selected from among an optionally substituted —NH-aryl, —NH-heteroaryl, aryl, heteroaryl, C3-C8-cycloalkyl- and heterocycloalkyl group, Q2 denotes hydrogen or a group selected from among an optionally substituted aryl, heteroaryl, C3-C8-heterocycloalkyl, C3-C8-cycloalkyl- and C1-C4-alkyl-C3-C8-cycloalkyl group, R10 is identical or different and denotes a group selected from among optionally substituted C1-C6-alkyl , C2-C6-alkenyl and C2-C6-alkynyl, —O—C1-C6-alkyl, —O—C2-C6-alkenyl, —O—C2-C6-alkynyl, C3-C6-heterocycloalkyl and C3-C6-cycloalkyl, or a group selected from among hydrogen, —CONH2, —COOR8, —OCON(R8)2, —N(R8)2, —NHCOR8, —NHCON(R8)2, —NO2and halogen, or adjacent groups R9 and R10 together denote a bridge of the formula 1370Y denotes O, S or NR11, m denotes 0, 1 or 2 R11 denotes hydrogen or C1-C2-alkyl, and R12 denotes hydrogen or a group selected from among optionally substituted phenyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, —C1-C3-alkyl-phenyl, —C1-C3-alkyl-pyridyl, —C1-C3-alkyl-pyrazinyl, —C1-C3-alkyl-pyrimidinyl and —C1-C3-alkyl-pyridazinyl, and R13 denotes C1-C6-alkyl.
- 4) The compounds according to claim 3, wherein
R1 denotes hydrogen, R2 denotes CH3, and R7 denotes hydrogen.
- 5) A pharmaceutical composition comprising a pharmaceutically effective amount of a compound of formula I according to claim 1 optionally combined with conventional excipients and/or carriers.
- 6) A method of inhibiting proliferation of cells in a patient in need thereof, said method comprising administering to a patient in need thereof a therapeutically effective amount of a compound of formula I according to claim 1.
- 7) The method according to claim 6 wherein the cells are tumour cells, endothelial, hair, intestinal, blood or progenitor cells.
- 8) A method of treating a disease or condition chosen from cancer, infections, inflammatory and autoimmune diseases said method comprising administering to a patient in need thereof a therapeutically effective amount of a compound of formula I according to claim 1.
- 9) A method of treating a disease or condition chosen from HIV, Kaposi's sarcoma, colitis, arthritis, Alzheimer's disease, glomerulonephritis, conditions related to wound healing, bacterial, fungal and/or parasitic infections, leukaemias, lymphoma, solid tumours, psoriasis, bone diseases and cardiovascular disease comprising administering to a patient in need thereof a therapeutically effective amount of a compound of formula I according to claim 1.
- 10) A process for preparing a compound of the formula (I) according to claim 1,
- 11) A compound of the formula (II),
- 12) A process for preparing a compound of the formula (I),
Priority Claims (1)
Number |
Date |
Country |
Kind |
101 43 272.0 |
Sep 2001 |
DE |
|
APPLICATION DATA
[0001] This application claims benefit to DE 101 43 272.0 filed Sep. 4, 2001 and U.S. provisional application No. 60/332681 filed Nov. 14, 2001.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60332681 |
Nov 2001 |
US |